---
title: "Trending | CTMX Surges 44% on Monday, Some Call options Surges 94%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279366042.md"
description: "On March 16, Eastern Time, Cytomx Therap options saw a total of 74657 contracts traded, with calls accounting for 73% and puts making up 26%."
datetime: "2026-03-17T04:20:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279366042.md)
  - [en](https://longbridge.com/en/news/279366042.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279366042.md)
---

# Trending | CTMX Surges 44% on Monday, Some Call options Surges 94%

On March 16, Eastern Time, Cytomx Therap options saw a total of 74657 contracts traded, with calls accounting for 73% and puts making up 26%.

Cytomx Therap has 117447 contracts outstanding, with calls accounting for 94% and puts making up 5%.

The top volume gainer was the 7 dollars Call option expiring on March 20, 2026, with 24537 contracts traded.

On the news front, Based on recent key news:

1\. March 16, CytomX Therapeutics announced positive interim Phase 1 data for its experimental cancer drug, varsetatug masetecan, showing robust efficacy in late-line colorectal cancer. This news led to a significant increase in stock price, reaching a new four-year high. The drug's promising results could establish it as a new standard of care for patients who have tried multiple treatments. Source: Reuters

2\. March 16, CytomX Therapeutics reported a decrease in operating expenses and a net loss for 2025, but maintained strong cash reserves, supporting its pipeline advancement. The financial update provided confidence in the company's ability to sustain operations and continue drug development. Source: Benzinga

3\. March 17, CytomX Therapeutics announced a proposed public offering of common stock and pre-funded warrants, aiming to raise $250 million. This move is expected to bolster the company's financial position and support ongoing clinical trials. Source: ReutersBiotech sector shows strong innovation.

Please note: The chart below does not include options expiring within five days.

![image](https://assets.lbctrl.com/h5hub/optrank/images/2026-03-17/ST_US_CTMX_en.png)

### Related Stocks

- [CTMX.US](https://longbridge.com/en/quote/CTMX.US.md)

## Related News & Research

- [BUZZ-CytomX drops on $250 mln equity raise](https://longbridge.com/en/news/279606950.md)
- [CytomX Unveils $250 Mln Offering Of Shares And Warrants To Advance Varseta-M And Other Pipeline](https://longbridge.com/en/news/279384196.md)
- [A Look At CAE’s (TSX:CAE) Valuation As Mixed Recent Returns Contrast With Undervalued Narrative Estimate](https://longbridge.com/en/news/282272014.md)
- [Weir Group executives receive final 2021 share awards with two‑year lock‑in](https://longbridge.com/en/news/282170302.md)
- [Beam Global Reports Full Year 2025 Operating Results | BEEM Stock News](https://longbridge.com/en/news/282247689.md)